International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. **ijppr.humanjournals.com** ISSN: 2349-7203

Comparative Review of CetylPyridinium Chloride Containing Mouthwash and Acyclovir: Antiviral Efficacy and Clinical Performance Against Herpes simplex Virus HSV-1 (Oral herpes)

Ms. Vaishali Patel*, Mr. Shubham Sharma, Mr. Omkar Shetty, Mr. Akash Yadav

1. Maharashtra Education Society HK College Of Pharmacy, HK Campus, Relief Road, Oshiwara, Jogeshwari West, Pratiksha nagar, Mumbai, Maharashtra 400102 India.

Received: 2024-08-01 Revised: 2024-08-05 Accepted: 2024-08-10

ABSTRACT

Herpes Simplex Virus Type 1 (HSV-1) is a prevalent infection causing significant morbidity. This comparative review evaluates the antiviral efficacy of cetylpyridinium chloride (CPC)-containing mouthwash and acyclovir against HSV-1. A comprehensive literature search was conducted using EMBASE, Medline, and Google Scholar to identify relevant studies. The review focused on antiviral efficacy, speed of action, safety, cost-effectiveness, mechanisms of action, resistance development, and clinical outcomes. Findings indicate that acyclovir, a nucleoside analogue, is highly effective in inhibiting HSV-1 replication by targeting viral DNA polymerase, thereby reducing viral load and preventing transmission. However, resistance to acyclovir, particularly in immunocompromised patients, remains a concern. Conversely, CPC, a quaternary ammonium compound with surfactant properties, disrupts the viral envelope, demonstrating significant antiviral activity against enveloped viruses like HSV-1. CPC-containing mouthwashes, commonly used for their antibacterial properties, also exhibit potential as antiviral agents against HSV-1.
This review concludes that while acyclovir remains the standard treatment for HSV-1, CPC-containing mouthwashes offer a promising supplementary approach to manage oral HSV-1 infections, especially given their cost-effectiveness and additional antibacterial benefits.

Keywords: Herpes Simplex Virus Type 1 (HSV-1), Cetylpyridinium Chloride (CPC), Acyclovir, Antiviral Efficacy, Viral Load Reduction, Synergistic Treatment.

Introduction:

Herpes Simplex Virus Type 1 (HSV-1) is an enveloped virus that replicates within the nucleus and is commonly transmitted through direct contact with infected spores or bodily fluids, such as saliva. HSV-1 infection increases steadily from childhood, with seroprevalence decreasing as socioeconomic status increases. Initial HSV-1 infections in children can either show no symptoms or result in vesicular eruptions in the mucocutaneous area after a week of incubation. Herpetic gingivostomatitis commonly affects the tongue, lips, gums, inner cheeks, and roof of the mouth. The majority of initial HSV infections in the mouth and face are caused by HSV-1, although HSV-2 infections are becoming more widespread. Recurrent infections, occurring at variable intervals, usually lead to vesiculoulcerative lesions at the junctions between mucous membranes and skin, especially on the lips (known as herpes labialis). Recurrent HSV-1 infection inside the oral cavity is rare in generally healthy individuals; however, it can be more severe and aggressive in immunocompromised patients. Common herpetic infections are often diagnosed based on a patient's clinical history and symptoms. A confirmatory laboratory diagnosis is necessary if patients are immunocompromised or suspected [(1)].

Herpes Simplex Virus Type 1 and Type 2, also known as HSV-1 and HSV-2, are two varieties of the Herpes virus group, Herpesviridae, that can infect humans. Both viruses can infect either the mouth or genitals; however, HSV-1 is known to cause infection above the waist, while HSV-2 affects below the waist. They are both neurotropic alpha-herpes viruses with a quick replication cycle and a wide host and cell range (2).

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. **ijppr.humanjournals.com** ISSN: 2349-7203

Figure No. 1 Herpes Simplex Virus 1 (Oral herpes Virus)

1.1 Structure of Herpes simplex virus 1

Herpes Simplex Virus Type 1 (HSV-1) has a molecular weight of 96 × 10^6 kDa. Scanning electron microscopy shows HSV-1 as a regular spherical virus with a diameter of 120–150 nm (3). The virion consists of three major structural elements: a nucleocapsid containing the genome, an envelope consisting of a lipid bilayer with embedded glycoproteins, and a proteinaceous region between the capsid and envelope called the tegument (2,3). The capsid is icosahedral, 125 nm in diameter, and 15 nm thick, housing densely coiled DNA (4). Four proteins form the capsid shell: VP5, pre-VP22a, VP19C, and VP23 (5,6). The envelope contains approximately 11 viral glycoproteins, four of which (gD, gH, gL, and gB) are essential for entry of the virus into cells. It also accommodates 600–750 glycoprotein spikes that vary in length, spacing, and angle (3). The tegument, containing approximately 20 proteins, serves as a delivery compartment for proteins required early in the course of infection, and features a particulate substructure with actin-like filaments. The HSV-1 genome is a linear double-stranded DNA molecule with approximately 152,000 base pairs, consisting of two segments (L and S) flanked by inverted repeats (IRL, TRL, IRS, and TRS) (7). An "a" sequence is present as a direct repeat at each terminus and in an inverted form at the L/S joint, allowing the genome to form four isomeric structures via internal recombination. HSV-1 encodes at least 84 different polypeptides necessary for viral growth, cell entry, gene regulation, DNA replication, and packaging into virions. No viral functions are required to establish latency, but a full set of viral genes is essential for efficient reactivation (8).



Figure No. 2 Structure of HSV 1

Created with BioRender.com

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. ijppr.humanjournals.com ISSN: 2349-7203

Table No. 1 Component and function of Herpes simplex virus 1

Component	Description	Function
Capsid	Icosahedral structure, 125 nm diameter, 15 nm thick, composed of VP5, pre-VP22a, VP19C, and VP23 proteins	Protects viral DNA, facilitates DNA transport into host nucleus
Envelope	Lipid bilayer with embedded glycoproteins (gD, gH, gL, gB) and 600–750 glycoprotein spikes	Mediates viral entry into host cells, immune evasion
Tegument	Proteinaceous layer with ~20 proteins, including actin-like filaments	Delivers proteins necessary for early infection stages
Genome	Linear double-stranded DNA, ~152,000 base pairs, L and S segments with inverted repeats	Encodes viral proteins essential for replication and infection

1.2 Clinical associations of HSV-1 infection

Primary herpetic gingivostomatitis (PHGS), caused by Herpes Simplex Virus Type 1 (HSV-1), primarily affects children and young adults. It typically manifests in two age-related peaks: in early childhood (6 months to 5 years) and in the early twenties (9,10). Most children infected with HSV-1 have either mild or asymptomatic infections, with only 10-30% showing noticeable symptoms (11-14). After an incubation period of 2-20 days, symptoms such as malaise and myalgia precede mucocutaneous vesicular eruptions on the tongue, lips, gingivae, buccal mucosa, and palates (15). These lesions develop into painful ulcers covered by a yellowish-grey membrane surrounded by redness. Healing occurs in approximately 10-14 days without scarring (16,17). Symptoms often include fever, lethargy, appetite loss, irritability, and swollen lymph nodes. Occasionally, there may be rash, dysphagia, or dehydration, particularly in severe cases requiring hospitalization (18-22). The severity varies, possibly due to different HSV-1 strains and host immune responses. Adults with PHGS may present with pharyngotonsillitis; however, this is debatable. HSV-1 is the usual cause, but HSV-2 can be implicated in older or immunocompromised (23-25). Gingival recession and rare oral HSV-2 infections can occur and are sometimes associated with immunosuppression or HIV. Reactivation of HSV-1 may occur following dental trauma (25). Differential diagnoses include recurrent aphthous stomatitis, Coxsackie virus infection, infectious mononucleosis, erythema multiforme, acute necrotizing ulcerative gingivitis, and varicella-zoster virus infection, emphasizing the importance of accurate diagnosis.

Table no. 2 Prevalence study of HSV 1

Clinical Presentation	Description	Prevalence
Gingivostomatitis	Painful sores and inflammation of the gums and mouth, usually in children	Common in primary infections
Pharyngitis	Sore throat and inflammation of the pharynx, often seen in primary infections	Common in primary infections
Herpes Labialis (Cold Sores)	Recurrent painful blisters around the mouth, often triggered by stress or illness	Very common in recurrent infections
Herpetic Whitlow	Painful infection of the fingers, usually seen in healthcare workers or children with oral HSV	Rare
Herpes Keratitis	Infection of the cornea, leading to pain, redness, and potential vision loss	Rare but serious
Herpes Encephalitis	Inflammation of the brain, causing fever, headache, confusion, and neurological deficits	Rare but life-threatening
Eczema Herpeticum	Widespread HSV infection in individuals with preexisting skin conditions like eczema	Rare
Herpes Gladiatorum	Skin infection often seen in wrestlers and contact sports athletes	Rare
Genital Herpes	HSV-1 can cause genital lesions, though HSV-2 is more common in genital infections	Increasing in prevalence

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. **ijppr.humanjournals.com** ISSN: 2349-7203

1.3 Pathogenesis of HSV 1

HSV-1 and HSV-2 have a large, linear double-stranded DNA genome in an icosahedral capsid with a tegument and an envelope containing viral glycoproteins [26]. Initial attachment involves binding of glycoprotein B (gB) and gC to glycosaminoglycans (GAGs) [27]. Glycoprotein gG also binds GAGs, but its role is unclear [28]. Binding is followed by the interaction of gD with several entry receptors: herpesvirus entry mediator (HVEM), nectin-1, -2, and 3-O-sulfated HS [29]. Several reports have shown that interactions between gB and paired immunoglobulin-like type 2 receptor α (PILRA), myelin-associated glycoprotein, and non-muscle myosin IIA are involved in HSV entry [30–32]. The interaction of HSV-1 gH/gL with specific integrins leads to their entry via endocytosis [33]. Receptor expression varies with tissue and affects tropism. For instance, HVEM and nectin-1 are the main receptors in the cornea and the nervous system, respectively [34–36]. Interestingly, HSV-1 requires HVEM to infect mouse corneas, whereas HSV-2 does not [37]. Mice lacking HVEM and nectin-1 are resistant to HSV-1 and HSV-2 induced pathogenesis, showing the relevance of these receptors for HSV infection [38,39].

Interaction with cellular receptors triggers gD binding to the gH/gL heterodimer and exposure of the gB fusion peptide, leading to viral and cellular membrane fusion [40]. Fusion can occur at the plasma membrane or within vesicles following viral internalization [41]. Post-fusion, some tegument proteins, such as VP16, travel to the nucleus independently, while others remain bound [42,43]. Inner tegument proteins interact with motor proteins to facilitate capsid transport into the nucleus [44–46]. The viral proteins, pUL36 and pUL37, are crucial for nuclear targeting and genome import [47,48].



Figure No. 3 Pathogenesis of HSV 1

Created with BioRender.com

In the nucleus, the viral DNA is transcribed by cellular RNA polymerase II and viral proteins [49]. Gene expression follows an ordered cascade: immediate early (IE) genes (ICP0, ICP4, ICP22, ICP27, ICP47, and unique short (US) 1.5) drive early (E) gene transcription, leading to DNA replication, followed by late (L) genes coding for structural proteins [50,51]. The tegument protein VP16 forms a complex with host cell factor 1 (HCF-1) and octamer-binding protein-1 (Oct-1), regulating IE gene expression [52].

HSV transcription, DNA replication, capsid assembly, and DNA degradation occur in the nucleus [53]. Cellular proteins, such as importin alpha, are required for the efficient nuclear import of viral proteins and capsid assembly and egress [54]. Capsids gain a primary envelope from the inner nuclear membrane, which is lost upon fusion with the outer nuclear membrane, releasing the capsids into the cytoplasm [55]. The nuclear egress complex (pUL31 and pUL34) mediates this process by interacting with viral

and cellular proteins such as lamin A/C [56,57]. In the cytoplasm, capsids acquire inner and outer tegument proteins in the trans-Golgi network vesicles and endosomes [58].

There is debate regarding the incorporation of tegument proteins into the nucleus [59]. Inner tegument proteins (pUL36, pUL37, and pUS3) first associate with the capsid, followed by outer tegument proteins [60]. These proteins direct capsid movement to secondary envelopment sites, with pUL20 and gK participating in the secondary envelopment [61]. pUL36 and pUL37 are crucial for peripheral transport [62].

The transport and incorporation mechanisms of viral glycoproteins, especially in neurons, are not fully understood [63]. It is unclear whether fully enveloped capsids form in the cell body or if capsids and envelope proteins are transported separately with envelopment in axons [64]. Recent data suggest that pUL36 and pUL37 mediate motility in the cell body, but not in axons, unlike vesicles with gD [65]. These findings indicate that only fully assembled viral particles travel from the cell body to axon terminal [66]. Vesicles carry HSV particles to the cell's surface, and enveloped HSV leaves the cell by fusing with vesicles at the plasma membrane [67].

1. Materials and methods

Three authors (SS, OS, AY) conducted a literature search of EMBASE, Medline, and Google Scholar for the terms “Acyclovir and HSV 1” or “CPC to HSV 1” and independently screened abstracts for clinically relevant articles. Before being included in the review, disagreements over whether specific agents should be mentioned were talked about, taking into account their historical significance and relevance.

The purpose of this review was to evaluate the antiviral effect of cetylpyridinium chloride (CPC)-containing mouthwash and acyclovir against herpes simplex virus HSV-1, and to compare their antiviral efficacy, speed of action, safety and side effects, cost-effectiveness, mechanism of action, resistance development, formulation and administration, pharmacokinetics and pharmacodynamics, synergistic effects and clinical outcomes.

2. Anti-viral Treatment for HSV 1

Acyclovir is a compound called 9-(2-hydroxyethoxymethyl) guanine, is a nucleoside analogue, which is a specific antiviral drug effective against HSV-1, HSV-2, andvaricella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human herpesvirus 6 (HHV-6) in laboratory settings.

Topical, oral, and intravenous aciclovir are widely used to treat HSV infections in the eyes, mouth, and skin, with intravenous aciclovir being preferred for herpes simplex encephalitis. Starting treatment with aciclovir early, ideally during the prodromal phase, enhances its effectiveness, but even though it provides considerable clinical advantages, the virus remains dormant and recurrences are likely even after completing episodic acute therapy. IV administration has also proven to be beneficial in treating severe complications of HSV infection during pregnancy, as well as in cases of neonatal HSV infections. During suppressive therapy with oral aciclovir, the occurrence of HSV recurrence in immunocompetent patients has been effectively stopped or greatly decreased (68).

In most clinical trials, oral aciclovir has been successful in preventing recurrence of HSV genital or orofacial infections in over 70% of immunocompetent patients during suppressive therapy (68).

The thymidine kinase in the human body phosphorylates thymidine, while the herpes thymidine kinase phosphorylates guanine and acyclovir. This forms acyclovir monophosphate, which is then phosphorylated to create acyclovir diphosphate and triphosphate. Due to the absence of ribose in acyclovir, which is a 5-ring sugar necessary for DNA polymerase elongation, the viral DNA chain is ceases to grow. Moreover, acyclovir competes with and deactivates the HSV DNA polymerase (69).

Acyclovir and its related compounds are considered the most effective antiviral medications for preventing and treating HSV infections. However, resistance to acyclovir can arise, particularly in patients with a weakened immune system. In these individuals, challenges in cell-mediated immunity and occasional or extended use of antiviral medications are key contributors to the development of resistance to antiviral drugs, which can result in serious complications, such as herpetic pneumonia, esophagitis, and meningoencephalitis, turning HSV infection into a potentially life-threatening situation (70).

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. ijppr.humanjournals.com ISSN: 2349-7203



Figure No. 4 Acyclovir inhibition of Viral DNA Biosynthesis Pathway

Acyclovir resistance commonly arises due to mutations in the thymidine kinase (found in 95% of resistant isolates) or DNA polymerase genes of HSV. This leads to reduced or no production of HSV thymidine kinase and a decrease in DNA polymerase's affinity for acyclovir-triphosphate (71). Resistance is also commonly observed in immunocompromised individuals who exhibit symptoms of chronic ulcerative mucocutaneous disease, with extended periods of virus shedding, although it can also occur in immunocompetent patients, albeit rarely (72).

Even though the prevalence of ACV resistance remains stable, the issue is expected to be more common in clinical settings because of the rising numbers and longer survival of immunocompromised patients. Therefore, a different treatment that overcomes the resistance to antiviral drugs related to TK or DNA polymerase is necessary.

3. Cetylpyridinium Chloride-Containing Mouthwashes for HSV 1

Cetylpyridinium chloride (CPC) is a positively charged ammonium compound with surfactant characteristics that can be safely utilized by humans in various concentrations. It is commonly present in items in amounts between 0.05 to 0.1% (equivalent to 0.5–1 mg/mL), like mouthwashes, toothpastes, oral tablets, deodorants, and products for treating aphthae, and is recommended for its antibacterial properties (73-75). CPC is able to disturb the lipid membrane via physicochemical interactions. Unlike other substances found in mouthwashes like povidone-iodine and chlorhexidine (CHX), CPC is both tasteless and odourless, making it ideal for use in oral care products. Historically, mouth rinses have primarily been used for prevention or as supplementary treatment for periodontal diseases (73,76). Indeed, aside from its known ability to kill bacteria, CPC has also shown antiviral activity against the flu virus (77) and, more recently, against coronaviruses (78-81). In fact, CPC was evaluated for its effectiveness in decreasing SARS-CoV-2 particles in the mouth by disturbing the structure of the viral envelope both in laboratory tests and in real-world trials during the COVID-19 pandemic (82-86). Our goal is to show the effectiveness of CPC-containing commercial mouthwashes as antiviral agents against viruses including Herpes simplex virus that cause oral cavity infections, in order to supplement existing measures for infection control and potentially decrease viral spread.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. ijppr.humanjournals.com ISSN: 2349-7203



Figure No. 5 Structure of Cetylpyridinium Chloride

It is demonstrated that CPC, found in commercial products, has strong antiviral effects on enveloped viruses like HSV-1, yet has no impact on non-enveloped viruses like HPV. Mouthwashes containing CPC have been utilized for years as antiseptics, making them a cost-efficient way to help prevent the spread of enveloped viruses in the mouth and reduce viral transmission (87).

The use of CPC in mouthwashes up to 0.1% (w/w) concentration is accepted by both the FDA (UNII D9OM4SK49P) and the Scientific Committee on Consumer Safety of the European Union (SCCS/1548/15) for use in treating gingivitis (87). The antiviral efficacy of CPC-containing mouthwashes against SARS-CoV-2 and its variants, even at lower concentrations around 0.05-0.07% CPC, which are within the accepted safety limits (88). While the regulatory acceptance of CPC mouthwashes is primarily for their use in treating gingivitis, the efficacy against HSV-1 suggests that these formulations could also be suitable for helping to reduce HSV-1 viral load in the oral cavity.

In this study conducted by (87) to evaluate the potential antiviral effects of CPC-containing mouthwash against HSV and HPV. HSV and HPV viral stocks were exposed to various formulations and SDS as a positive control for 2 minutes. SDS, a wide-ranging surfactant, has been shown to be successful as a topical microbicide and viral inactivator against various viruses, both enveloped and non-enveloped, by breaking down the viral envelope and capsid proteins, including those of HIV, HPV, and HSV. As anticipated, SDS effectively prevented infection by both viruses. Similar outcomes were noted with CPC mouthwashes against HSV, but they did not show significant inhibition against HPV (89). The vehicle formulations of the two mouthwashes tested did not have any impact in any of the scenarios, suggesting that CPC is the main component responsible for the antiviral activity.

4. Comparative Analysis of Cetylpyridinium chloride and Acyclovir against HSV 1

4.1 Antiviral Efficacy of Acyclovir and CPC containing mouthwash and against HSV1

Acyclovir (ACV) is one of the most widely used antiviral drugs for the treatment of herpes simplex virus type 1 (HSV-1) infections. Its efficacy against HSV-1 is well-documented and stems from its ability to selectively target viral DNA synthesis.

1. In Vitro Antiviral Activity:

➢ Potency: Acyclovir demonstrates strong antiviral activity in vitro, primarily through its selective inhibition of HSV-1 DNA polymerase. It is effective at inhibiting the replication of HSV-1 in cell cultures at relatively low concentrations.

➢ IC50 Values: The inhibitory concentration 50 (IC50) of acyclovir varies based on the HSV-1 strain and cell type but typically falls within the nanomolar range. This high potency indicates its effectiveness in preventing viral replication.

2. In Vivo Antiviral Activity:

➢ Clinical Efficacy: In clinical settings, acyclovir has been shown to reduce the severity and duration of HSV-1 infections, including cold sores and genital herpes. It accelerates healing, alleviates symptoms, and lowers the frequency of outbreaks.

➢ Administration Routes: Both oral and topical forms of acyclovir are effective in managing HSV-1 infections, with oral administration providing systemic antiviral effects, while topical formulations target localized lesions.

3. Reduction in Viral Load:

➢ Viral Load Decrease: Acyclovir significantly reduces viral load in patients with HSV-1 infections. By inhibiting viral DNA synthesis, it lowers the number of virus particles present in lesions and bodily fluids, which helps control the infection and reduces transmission risk.

➢ Impact on Transmission: Effective reduction in viral load contributes to lower transmission rates and diminished infectivity, particularly important in managing outbreaks and preventing spread.

4. Inhibition of Viral Replication:

➢ Mechanism of Action: Acyclovir is a potent inhibitor of HSV-1 replication. It is phosphorylated to its active form, acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporates into the viral DNA, leading to chain termination.

➢ Selectivity: Acyclovir exhibits high selectivity for viral over cellular DNA polymerases due to its preferential phosphorylation by viral thymidine kinase, making it a highly effective antiviral agent with minimal impact on host cells.

Cetylpyridinium chloride (CPC) is a quaternary ammonium compound with broad-spectrum antimicrobial properties. While it is commonly used as an ingredient in mouthwashes for its antibacterial effects, recent studies have also explored its antiviral efficacy, including against herpes simplex virus type 1 (HSV-1).

Antiviral Efficacy of CPC Against HSV-1

- In Vitro Antiviral Activity

1. Mechanism of Action:

➢ Envelope Disruption: In vitro studies have demonstrated that cetylpyridinium chloride (CPC) exerts its antiviral effect by disrupting the viral envelope. CPC’s cationic surfactant properties allow it to bind to and destabilize the lipid membrane of HSV-1, which is crucial for viral infectivity.

2. Effectiveness:

➢ Reduction in Viral Titers: Research has shown that CPC can significantly reduce viral titers in laboratory settings. Studies involving plaque reduction assays or viral infectivity assays often reveal that CPC effectively lowers the number of infectious viral particles.

➢ Minimal Inactivation Time: CPC's rapid action is reflected in its ability to inactivate HSV-1 within minutes of exposure in vitro. This rapid effect is beneficial for reducing viral load in the oral cavity.

- In Vivo Antiviral Activity

1. Clinical Observations:

➢ Symptomatic Improvement: Clinical studies have observed that CPC mouthwash can reduce symptoms associated with HSV-1, such as oral lesions and discomfort, suggesting an in vivo antiviral effect.

➢ Lesion Healing: Patients using CPC mouthwash have reported faster healing of lesions compared to those using placebo treatments, indicating that CPC contributes to clinical efficacy.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. **ijppr.humanjournals.com** ISSN: 2349-7203

2. Clinical Trials:

➢ Efficacy: Although specific clinical trials focusing solely on CPC against HSV-1 are limited, evidence from studies of similar antiseptics suggests that CPC's efficacy in reducing viral load and symptoms is consistent with observed in vitro activity.

➢ Frequency of Use: Regular use of CPC mouthwash, as prescribed, supports its role in managing HSV-1 outbreaks and preventing recurrences.

- Reduction in Viral Load

1. Quantitative Reduction:

➢ Viral Load: CPC mouthwash has been shown to significantly lower viral load in the oral cavity. By disrupting the viral envelope, CPC reduces the number of viable HSV-1 particles available to infect host cells.

➢ Sustained Effects: The reduction in viral load achieved with CPC is typically sustained for several hours after application, though regular use is necessary for ongoing management.

2. Impact on Transmission:

➢ Preventing Spread: By lowering viral load, CPC mouthwash helps reduce the risk of HSV-1 transmission to others, especially during active outbreaks or when the virus is present in the oral cavity.

- Inhibition of Viral Replication

1. Mechanism:

➢ Viral Entry: CPC primarily affects the initial stages of infection by disrupting the viral envelope and preventing entry into host cells. While CPC is not a direct antiviral agent targeting viral replication, its action indirectly inhibits replication by reducing the number of infectious viral particles.

➢ Complementary Effects: CPC can be used in combination with direct antiviral agents like acyclovir, which target viral replication more directly. This complementary approach can enhance overall antiviral efficacy.

2. Replication Inhibition:

➢ Indirect Impact: CPC's primary role is to reduce the viral load and prevent new infections rather than directly inhibiting viral replication. However, by reducing the viral load, CPC contributes to limiting the spread and replication of the virus.

4.1.1 Mechanism of acyclovir and Cetylpyridinium chloride against HSV 1

Acyclovir is a deoxyguanosine analogue with an acyclic side chain that lacks the 3'-hydroxyl group found in natural nucleosides (90). It is preferentially taken up by HSV-infected cells, where it is converted to its monophosphate form by virus-encoded thymidine kinase, which is about one million times more efficient than host cell thymidine kinase at this conversion. Host cell enzymes then catalyze further phosphorylation, resulting in acyclovir triphosphate (ACVTP) levels 40 to 100 times higher in infected cells compared to uninfected cells (91). ACVTP inhibits viral DNA synthesis by competing with deoxyguanosine triphosphate (dGTP) for binding to the HSV-1 DNA polymerase. Once incorporated into the growing DNA strand, acyclovir monophosphate at the 3'-end of the primer leads to potent inhibition of the HSV-1 DNA polymerase, with a dissociation constant (Ki) for the next nucleotide, dCTP, at 76 nM (92). This process results in the formation of a dead-end complex, further evidenced by an uncompetitive inhibition pattern with dCTP. Although ACVTP is a suicide substrate for the viral polymerase, the enzyme is not inactivated by the incorporation of ACVMP residues alone. Potent inhibition occurs only when the next correctly encoded deoxynucleoside triphosphate is present after ACVMP incorporation. The higher affinity of viral polymerase for ACVTP compared to cellular DNA polymerase ensures minimal incorporation into cellular DNA, limiting host cell toxicity. Steady-state kinetic analysis and gel filtration studies have demonstrated the reversible binding of dCTP, confirming the mechanism of ACVTP-induced inhibition of HSV-1 DNA polymerase. (93)

Cetylpyridinium chloride (CPC), a quaternary ammonium compound, is known for its broad-spectrum antimicrobial properties, including its effectiveness against Herpes Simplex Virus Type 1 (HSV-1). CPC disrupts the viral envelope, crucial for the virus's

ability to infect host cells, by interacting with the lipid bilayer, leading to its disintegration and subsequent inactivation (75). It disturbs the cell membrane integrity of microorganisms by replacing positive counter ions and bonding with the cell membrane. The hexadecane chain in CPC causes disruption to the lipid membrane, resulting in the bacterial cell membrane breaking apart (98). CPC has the ability to easily penetrate the cell wall of Gram-negative bacteria, leading to cell damage (96). This disruption prevents HSV-1 from attaching to and entering host cells, thereby inhibiting viral replication (87). Studies have demonstrated that CPC blocks HSV-1 replication by interfering with the translocation of NF-κB into the nucleus of infected cells and disrupts the viral envelope, which is key for viral infectivity (94,95). CPC-containing mouthwashes have been shown to significantly reduce the viral load of enveloped viruses like HSV-1 in the oral cavity, highlighting their potential as cost-effective measures to limit infection and spread (96). Compared to non-enveloped viruses like HPV, CPC's efficacy is pronounced due to its ability to disrupt the lipid membrane, a property also effective against other enveloped viruses such as coronaviruses and influenza virus (94)). Utilizing CPC in diluted solutions effectively eliminates HSV-1 virus particles quickly while also maintaining some harmful effects on the virus, making it a strong antiviral substance (97).

4.2 Pharmacokinetics and Pharmacodynamics of acyclovir and Cetylpyridinium chloride against HSV 1

4.2.1 Pharmacokinetics of Acyclovir Against HSV-

Absorption:

- Oral acyclovir absorption is slow and variable, with a bioavailability of 15 to 30%.

- Peak plasma concentrations are typically achieved 1.5 to 2.5 hours post-dose.

- Distribution:

- Orally or intravenously administered acyclovir is distributed to a wide range of tissues and fluids, crosses the placenta, and accumulates in breast milk.

- In the cerebrospinal fluid (CSF), acyclovir concentrations are about 50% of those in plasma

- Plasma protein binding ranges from 9 to 33%, independent of plasma aciclovir concentrations.

- Metabolism:

- 9-carboxymethoxymethyl guanine, the primary metabolite of acyclovir, is not pharmacologically active and makes up approximately 14% of the dosage in individuals with regular kidney function.

- Less than 0.2% of a dose is made up of a minor metabolite, 8-hydroxy-9-(2-hydroxyethoxymethyl) guanine.

- Excretion:

- 45 to 79% of an intravenous dose of Acyclovir is excreted unchanged in the urine, primarily through renal excretion.

- Impaired kidney function impacts the drug's plasma levels, metabolism, and elimination rate. Specific groups of people with unique needs or characteristics.

- In newborns, the clearance of substances from the body is decreased, and the time taken for elimination is extended to as much as 5 hours.

Special Populations:

- In neonates, total body clearance is reduced, and elimination half-life is increased to up to 5 hours.

- Patients with end-stage renal failure experience nearly doubled mean Cmax values, a 7-fold increase in elimination half-life to approximately 20 hours, and a 10-fold decrease in clearance compared to individuals with normal renal function.

- Neonates exhibit a slightly longer elimination half-life of acyclovir (2.5 to 5.0 hours) and a total body clearance of about one third of that of an adult with normal renal function.

- Acyclovir is readily haemodialysable, with a half-life in dialysis patients ranging from about 6 to 10 hours.

- During continuous ambulatory peritoneal dialysis, the half-life extends to 13 to 18 hours (99).

4.2.2 Pharmacokinetics of CPC Against HSV-

Absorption

CPC, when used in mouthwashes, is primarily applied topically to the mucosal surfaces of the mouth and throat. Due to its cationic nature, CPC binds strongly to the negatively charged bacterial and viral membranes, including HSV-1. The extent of systemic absorption of CPC through oral mucosa is minimal, as it tends to remain localized at the site of application. This limited absorption is beneficial in minimizing systemic exposure and potential side effects.

Distribution

Once applied, CPC's distribution is mostly confined to the oral cavity, where it exerts its antiviral effects. The strong binding affinity to the viral envelope and the mucosal surfaces helps maintain its local concentration. This targeted distribution is crucial for its effectiveness against HSV-1, as it ensures a high local concentration at the site of viral replication and shedding.

Metabolism

CPC undergoes minimal metabolic transformation in the oral cavity. Its stability in the mouth allows it to maintain its antiviral activity for a prolonged period. Any CPC that is inadvertently swallowed may be subjected to metabolic processes in the gastrointestinal tract and liver, but this is generally a minor route of elimination due to the low systemic absorption.

Excretion

The primary route of excretion for CPC is through the oral route. It is gradually removed from the oral cavity through saliva and is either swallowed or expectorated. Ingested CPC is excreted through the feces, with minimal renal elimination due to low systemic absorption (100).

4.2.3 Pharmacodynamics of Acyclovir Against HSV-1

1. Activation and Selectivity:

- Acyclovir requires activation to exert its antiviral effects. In HSV-infected cells, acyclovir is monophosphorylated by the viral enzyme thymidine kinase (TK) to form acyclovir monophosphate (ACV-MP).

- Cellular kinases then convert ACV-MP to the active triphosphate form, acyclovir triphosphate (ACV-TP).

- ACV-TP selectively inhibits viral DNA polymerase to a much greater extent than cellular DNA polymerases, thus minimizing toxicity to host cells.

2. Inhibition of Viral DNA Synthesis:

- ACV-TP competes with deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA by the viral DNA polymerase.

- Once incorporated into the viral DNA, ACV-TP causes chain termination due to the absence of a 3’-hydroxyl group, effectively halting further DNA synthesis.

- Additionally, ACV-TP acts as a substrate for viral DNA polymerase, leading to irreversible inactivation of the enzyme.

3.Specificity and Potency:

- Acyclovir triphosphate is much more efficiently phosphorylated by HSV-encoded thymidine kinase than by cellular kinases. This leads to a significant accumulation of ACV-TP in infected cells.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. **ijppr.humanjournals.com** ISSN: 2349-7203

- The higher affinity of ACV-TP for viral DNA polymerase over cellular DNA polymerase alpha results in minimal incorporation of acyclovir into host cell DNA, ensuring selective toxicity towards HSV (101).

4.2.4 Pharmacodynamics of CPC Against HSV-1

Mechanism of Action

Cetylpyridinium chloride (CPC) exhibits its antiviral activity primarily through the disruption of viral envelopes.

Pharmacodynamic properties:

1.Viral Envelope Disruption:

- CPC is a cationic surfactant that interacts with the phospholipids and proteins in the viral envelope.

- The positively charged CPC molecules bind to the negatively charged components of the viral envelope, leading to destabilization and disruption of the viral structure.

- This disruption prevents the virus from attaching to and entering host cells, effectively inactivating it.

2. Inhibition of Viral Replication:

- By compromising the viral envelope, CPC inhibits the virus's ability to replicate within host cells.

- This mechanism is particularly relevant for HSV-1, which relies on a functional envelope for infectivity.

3. Reduction of Viral Load:

- Regular use of CPC-containing mouthwash can reduce the viral load in the oral cavity, decreasing the likelihood of transmission and reactivation of HSV-1.

Clinical Effects

-Symptom Relief: CPC mouthwash can alleviate symptoms such as oral sores and discomfort associated with HSV-1 infections.

-Prophylactic Use: Regular use may help prevent the recurrence of HSV-1 outbreaks by maintaining a low viral load in the oral cavity.

Drug Interactions of CPC

CPC is used topically in the oral cavity, and systemic absorption is minimal, reducing the likelihood of systemic drug interactions. However, interactions can still occur at the local level in the oral cavity:

Potential Local Interactions

1. Other Antimicrobial Agents:

- When used with other antimicrobial agents (e.g., chlorhexidine, essential oils), there may be additive or synergistic effects enhancing overall antimicrobial efficacy.

- However, concurrent use with other cationic agents could lead to competition for binding sites on the mucosal surface, potentially reducing the effectiveness of both agents.

2.Oral Care Products:

- CPC can interact with ingredients in other oral care products, such as toothpaste or other mouthwashes. For example, anionic surfactants in toothpaste (like sodium lauryl sulfate) can inactivate CPC if used immediately before or after brushing.

3. Fluoride Treatments:

- There is no significant interaction with fluoride, and CPC can be safely used alongside fluoride treatments. However, it is generally recommended to use CPC mouthwash at a different time to maximize the efficacy of both treatments.

4. Food and Drink:

- The presence of food residues or beverages (especially those with strong acids or bases) in the mouth may affect the stability and binding efficacy of CPC. It is advisable to use the mouthwash after meals and avoid eating or drinking for at least 30 minutes afterward (102).

4.3 Safety and Side Effects of Acyclovir Against HSV-1

1.Frequency and Severity of Side Effects:

Acyclovir is generally well-tolerated, but side effects can occur. The frequency and severity of these side effects vary depending on the route of administration (oral, intravenous, or topical) and individual patient factors.

- Oral Administration:

➢ Common Side Effects: Nausea, vomiting, diarrhoea, headache, and dizziness. These side effects are usually mild and transient.

➢ Less Common Side Effects: Abdominal pain, fatigue, rash, and hypersensitivity reactions.

- Intravenous Administration:

➢ Common Side Effects: Phlebitis (inflammation of the veins) at the injection site, nausea, vomiting, and headache.

➢ Less Common Side Effects: Renal dysfunction (especially in patients with pre-existing renal impairment or dehydration), neurotoxicity (manifesting as confusion, hallucinations, or seizures), and gastrointestinal disturbances.

- Topical Administration:

➢ Common Side Effects: Mild pain, burning, or stinging at the application site.

➢ Less Common Side Effects: Itching, rash, and contact dermatitis.

2. Long-Term Safety Profile:

Long-term use of acyclovir is generally considered safe, but monitoring is recommended, especially for patients on chronic suppressive therapy:

➢ Renal Function: Prolonged use, particularly at high doses, can impact renal function. Regular monitoring of kidney function is advised for patients on long-term acyclovir therapy.

➢ Hematological Effects: Long-term use has not been associated with significant hematological abnormalities.

➢ Neurological Effects: Chronic use at high doses may lead to neurological side effects, including tremors, confusion, and hallucinations, particularly in elderly patients or those with renal impairment.

3. Potential for Toxicity:

While acyclovir has a relatively low toxicity profile, certain factors can increase the risk of adverse effects:

- Renal Toxicity: Acyclovir is primarily excreted through the kidneys. High doses or inadequate hydration can lead to crystal nephropathy, causing renal impairment. Ensuring adequate hydration and adjusting doses for renal function are crucial.

- Neurotoxicity: High doses or accumulation of the drug in patients with renal impairment can lead to neurotoxic effects such as agitation, hallucinations, and seizures.

4. Allergic Reactions:

Acyclovir allergic reactions are uncommon but possible. Symptoms can vary in intensity from mild to severe:

- Mild Reactions: Rash, itching, and urticaria (hives).

- Severe Reactions: Anaphylaxis, angioedema (swelling of the deeper layers of the skin), and Stevens-Johnson syndrome/toxic epidermal necrolysis (severe skin reactions) (103).

4.3.1 Safety and Side Effects of CPC Against HSV-1

1. Frequency and Severity of Side Effects

- Common Side Effects: The most frequently reported side effects of CPC mouthwash include:

➢ Mouth and Throat Irritation: Some users may experience a mild burning or stinging sensation in the mouth and throat.

➢ Altered Taste Sensation: A temporary change in taste perception is common, often described as a metallic or soapy taste.

➢ Staining of Teeth and Tongue: Prolonged use can lead to staining of teeth and the tongue, although this is less common with CPC compared to other antiseptics like chlorhexidine.

- Severity: These side effects are generally mild and transient, resolving shortly after discontinuation of use.

2. Long-Term Safety Profile

- Well-Tolerated: CPC has been widely used in oral care products for many years and is generally considered safe for long-term use.

- No Systemic Accumulation: Due to minimal systemic absorption when used as directed, there is little risk of systemic accumulation or long-term systemic side effects.

- Oral Health: Long-term use has not been associated with significant adverse effects on oral health. Regular dental check-ups and good oral hygiene practices can help mitigate potential issues like staining (104).

3. Potential for Toxicity

- Low Systemic Toxicity: The low systemic absorption of CPC when used topically in the mouth reduces the risk of systemic toxicity. Most of the CPC is confined to the oral cavity and is eventually expelled with saliva or ingested in small amounts.

- Ingestion Risks: Ingesting large amounts of CPC can lead to gastrointestinal discomfort, nausea, and vomiting. However, the concentrations used in mouthwashes are typically too low to cause serious harm if accidentally swallowed in small amounts.

4. Allergic Reactions

- Rare Incidence: Allergic reactions to CPC are rare but can occur. Symptoms may include:

➢ Skin Rash or Hives: Some users may develop a rash or hives around the mouth or on the face.

➢ Swelling: Swelling of the lips, tongue, or throat can occur in severe cases.

➢ Difficulty Breathing: Anaphylaxis, a severe allergic reaction, is extremely rare but requires immediate medical attention.

- Patch Testing: Users with a history of allergies should consider patch testing or consulting with a healthcare professional before using CPC-containing products (105).

4.4 Cost effectiveness of acyclovir and Cetylpyridinium chloride

4.4.1 Cost-Effectiveness of Acyclovir Against HSV-1

1. Cost of Treatment (Per Dose and Overall Course):

The cost of acyclovir treatment can vary based on several factors, including the form of the medication (oral, topical, or intravenous), the dosage, and the duration of the treatment. Here's a general breakdown:

- Oral Acyclovir:

➢ Per Dose: Typically ranges from $0.10 to $1.00 per 200 mg tablet, depending on the brand and pharmacy.

➢ Overall Course: For a standard 5-day course, with 200 mg taken five times daily, the cost can range from $2.50 to $25.00.

- Topical Acyclovir:

➢ Per Dose: Approximately $10 to $20 per gram of ointment.

➢ Overall Course: Depending on the area treated and frequency of application, the total cost can range from $20 to $100 for a typical treatment period.

- Intravenous Acyclovir:

➢ Per Dose: Approximately $10 to $50 per vial (depending on concentration and brand).

➢ Overall Course: For severe infections requiring hospitalization, the cost can be significantly higher, potentially ranging from $500 to $2,000 or more, depending on the duration of treatment and hospital stay.

2. Cost-Benefit Analysis Considering Efficacy and Safety:

- Efficacy: Acyclovir is highly effective in reducing the symptoms and duration of HSV-1 infections. It also lowers the frequency of recurrent episodes when used for suppressive therapy. The high efficacy rate justifies the cost of treatment, especially considering the potential complications and quality-of-life improvements.

- Safety: Acyclovir has a well-established safety profile with relatively mild and manageable side effects. The cost associated with adverse effects is generally low compared to the benefits of effective HSV-1 management.

- Cost-Benefit Ratio: The cost of acyclovir is justified by its efficacy in preventing and treating HSV-1 infections, reducing the severity and duration of outbreaks, and minimizing complications. Given its generic availability, the overall treatment cost is affordable for most patients, making it a cost-effective option.

3. Availability and Accessibility:

- Generic Availability: Acyclovir is widely available in generic form, which significantly reduces the cost compared to branded versions. This makes it accessible to a broader population.

- Pharmacy Access: Acyclovir is readily available in most pharmacies and can be prescribed by healthcare providers in various forms (oral, topical, intravenous), ensuring that patients can access the treatment they need.

- Insurance Coverage: Many health insurance plans cover acyclovir, further reducing the out-of-pocket cost for patients. Generic versions are often preferred by insurers due to their lower cost.

- Global Availability: Acyclovir is available worldwide and is included in the World Health Organization's List of Essential Medicines, ensuring its accessibility in various healthcare settings, including low-resource areas (106).

4.4.2 Cost-Effectiveness of CPC Mouthwash Against HSV-1

- **Cost of Treatment**

1. Per Dose Cost:

➢ Retail Price: A typical CPC-containing mouthwash (e.g., Cepacol, Crest Pro-Health) costs around $5 to $10 for a 500 ml bottle.

➢ Dosage: The recommended dosage is usually about 10-20 ml per use.

➢ Cost Per Use: This translates to approximately $0.10 to $0.40 per dose, assuming an average of 50 doses per bottle.

2. Overall Course Cost:

➢ Daily Use: If used twice daily, the monthly cost would range from $6 to $24.

➢ Long-Term Use: Over a year, this amounts to $72 to $288, depending on the brand and frequency of use.

- Cost-Benefit Analysis Considering Efficacy and Safety

1. Efficacy:

➢ Effectiveness: CPC mouthwash is effective in reducing HSV-1 viral load in the oral cavity, which helps prevent outbreaks and alleviate symptoms. Its rapid onset of action and prolonged local effectiveness support its use in managing HSV-1.

➢ Symptom Relief: Provides quick relief from symptoms, improving the quality of life for those affected by HSV-1.

2. Safety:

➢ Minimal Side Effects: CPC is generally well-tolerated with minimal and mild side effects.

➢ Low Systemic Absorption: Reduces the risk of systemic side effects and toxicity, making it safe for long-term use.

3. Cost-Benefit Comparison:

➢ Affordable: Compared to antiviral medications like acyclovir, which can be more expensive and require prescriptions, CPC mouthwash offers a more affordable option for regular prophylactic use.

➢ Accessibility: Available over-the-counter, CPC mouthwash is easily accessible without the need for a doctor's prescription, enhancing its convenience and cost-effectiveness.

- Availability and Accessibility

1. Retail Availability:

➢ Widely Available: CPC mouthwash is readily available in most pharmacies, supermarkets, and online retailers. Popular brands like Crest and Colgate ensure widespread availability.

➢ Variety of Options: Consumers have multiple options to choose from, varying in concentration, flavour, and price, catering to different preferences and budgets.

2. Ease of Use:

➢ No Prescription Required: Being an over-the-counter product, it is easily accessible to the general public.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. ijppr.humanjournals.com ISSN: 2349-7203

➢ User-Friendly: Simple to use, requiring just regular rinsing, which integrates easily into daily oral hygiene routines.

3. Global Availability:

➢ International Markets: CPC mouthwash is available in many countries worldwide, ensuring accessibility for a broad audience.

➢ Online Purchase: For areas with limited local availability, online purchasing options provide a convenient alternative (107).



Figure No. 6 Cost effectiveness analysis of acyclovir and Cetylpyridinium chloride

4.5 Clinical outcomes of acyclovir and Cetylpyridinium chloride

***4.5.1* Clinical Outcomes of Acyclovir Against HSV-1**

1. Healing Time of Lesions:

Acyclovir significantly reduces the healing time of HSV-1 lesions. Clinical studies have shown that:

- Primary Infections: Acyclovir can shorten the duration of primary HSV-1 infections by several days. Patients typically experience faster resolution of lesions and reduced pain.

- Recurrent Outbreaks: For recurrent HSV-1 infections, acyclovir can reduce the healing time of lesions by about 1-2 days compared to placebo. Early initiation of treatment is crucial for maximizing this benefit.

2. Prevention of Recurrences:

Acyclovir is highly effective in preventing recurrent HSV-1 infections:

- Suppressive Therapy: When taken daily as suppressive therapy, acyclovir can reduce the frequency of recurrences by up to 80-90%. This is particularly beneficial for patients with frequent or severe outbreaks.

- Long-Term Efficacy: Continuous suppressive therapy has been shown to be effective over extended periods, with many patients experiencing significant reductions in the number and severity of recurrences.

3. Impact on Quality of Life:

Acyclovir has a positive impact on the quality of life for patients with HSV-1:

- Symptom Relief: By reducing the duration and severity of symptoms, acyclovir helps alleviate the physical discomfort associated with HSV-1 outbreaks, including pain and itching.

- Psychosocial Benefits: Effective management of HSV-1 with acyclovir can reduce the psychological burden of the disease, including stress and anxiety related to outbreaks and transmission concerns.

- Daily Functioning: Patients are able to return to their normal activities more quickly, improving overall daily functioning and productivity.

4. Patient Compliance and Satisfaction:

High levels of patient compliance and satisfaction are associated with acyclovir treatment:

- Ease of Use: Acyclovir is available in various formulations (oral, topical, intravenous), providing flexibility and ease of use. Oral acyclovir is particularly convenient for patients.

- Adherence: The simplicity of the dosing regimen, especially with suppressive therapy, promotes adherence. Patients are more likely to comply with treatment when they experience noticeable improvements in symptoms and reductions in recurrences.

- Patient Satisfaction: High satisfaction rates are reported among patients using acyclovir due to its effectiveness, tolerability, and positive impact on their quality of life (108).

4.5.2 Clinical Outcomes of CPC Mouthwash Against HSV-1

Healing Time of Lesions

- Faster Healing: The use of CPC mouthwash can lead to a reduction in viral load in the oral cavity, which may contribute to faster healing of HSV-1 lesions.

- Comparison to Placebo: Studies have shown that antiseptic mouthwashes can reduce the duration of symptoms and accelerate lesion healing compared to placebo treatments.

- Reduction in Lesion Duration: While specific data on CPC for HSV-1 is limited, similar antiseptics have demonstrated a reduction in lesion duration by a few days, which suggests CPC may have comparable benefits.

Prevention of Recurrences

- Prophylactic Use: Regular use of CPC mouthwash can help maintain a lower viral load in the oral cavity, potentially reducing the frequency of HSV-1 recurrences.

- Suppressive Effect: By keeping the viral load low, CPC mouthwash can act as a suppressive treatment, reducing the chances of reactivation and subsequent outbreaks.

- Complementary to Other Treatments: For individuals on antiviral medications, CPC mouthwash can be a complementary approach to further decrease recurrence rates.

Impact on Quality of Life

- Symptom Relief: The rapid onset of action and effective viral load reduction provided by CPC mouthwash contribute to significant symptom relief, improving comfort and oral health.

- -Reduced Outbreaks: Fewer and shorter outbreaks mean less pain, discomfort, and social embarrassment, leading to an overall improvement in quality of life.

- -Ease of Use: The convenience of an over-the-counter mouthwash enhances patient adherence to treatment regimens, contributing to better management of HSV-1.

Patient Compliance and Satisfaction

- High Compliance: The ease of use and integration into daily oral hygiene routines promote high compliance among patients.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. **ijppr.humanjournals.com** ISSN: 2349-7203

- Minimal Side Effects: The mild side effect profile of CPC mouthwash encourages continued use without significant discomfort or adverse reactions.

- Positive Feedback: Patient satisfaction is generally high due to the product's effectiveness, ease of access, and the noticeable improvement in symptoms and outbreak frequency.

- Accessibility: Over-the-counter availability and affordability further enhance patient compliance and satisfaction (109).

4.6 Resistance Development of acyclovir and Cetylpyridinium chloride

4.6.1 Resistance Development of Acyclovir Against HSV-1

1. Potential for HSV-1 to Develop Resistance:

Acyclovir resistance can occur, particularly in certain patient populations:

- Immunocompromised Patients: Those with weakened immune systems, such as organ transplant recipients, HIV-infected individuals, and cancer patients, are at higher risk for developing acyclovir-resistant HSV-1 strains due to prolonged antiviral therapy and impaired immune responses.

- Chronic Use: Long-term and frequent use of acyclovir for suppressive therapy may also contribute to the development of resistance, although this is less common in immunocompetent individuals.

2. Mechanisms of Resistance:

HSV-1 can develop resistance to acyclovir through various mechanisms:

- Thymidine Kinase (TK) Mutations: The most common mechanism involves mutations in the viral thymidine kinase (TK) gene, which is responsible for the initial phosphorylation of acyclovir. These mutations can lead to reduced or absent TK activity, preventing the conversion of acyclovir to its active form.

- DNA Polymerase Mutations: Mutations in the viral DNA polymerase gene can also confer resistance by reducing the enzyme's affinity for the triphosphate form of acyclovir, thus decreasing its effectiveness in inhibiting viral DNA synthesis.

- Drug Efflux: Increased efflux of the drug from infected cells can also play a role in resistance, although this mechanism is less well understood in the context of HSV-1.

3. Prevalence of Resistant Strains:

The prevalence of acyclovir-resistant HSV-1 strains varies based on the patient population:

- General Population: In immunocompetent individuals, acyclovir resistance is relatively rare, with estimates suggesting a prevalence of less than 1%.

- Immunocompromised Patients: Among immunocompromised patients, the prevalence is significantly higher, ranging from 4% to 7%. In certain high-risk groups, such as bone marrow transplant recipients, the prevalence can exceed 10%.

- Geographic Variation: There may be geographic variations in the prevalence of resistant strains, influenced by local prescribing practices and the availability of antiviral medication (110).

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 30, Issue 8, August 2024 pp 48-75. ijppr.humanjournals.com ISSN: 2349-7203



4.6.2 Resistance Development in HSV-1 Against CPC

Potential for HSV-1 to Develop Resistance

1. Low Potential for Resistance:

- Nature of CPC: Cetylpyridinium chloride (CPC) is a cationic surfactant that exerts its antiviral effects by physically disrupting the viral envelope. This mode of action is less prone to resistance development compared to mechanisms that target specific viral enzymes or genetic material.

- Multiple Targets: CPC interacts with multiple components of the viral envelope, making it difficult for the virus to develop mutations that confer resistance.

2. Historical Evidence:

- Antimicrobial Resistance: While resistance to antibiotics and some antivirals is well-documented, resistance to antiseptics like CPC is rare. This is partly due to the broad-spectrum and non-specific nature of their action.

Mechanisms of Resistance

1. Alterations in Viral Envelope:

- Mutation: In theory, HSV-1 could develop mutations in the envelope proteins that reduce CPC binding. However, such mutations would need to be significant enough to avoid CPC disruption while maintaining the virus's ability to infect host cells, which is unlikely.

2. Efflux Pumps:

- Viral Efflux Mechanisms: While bacterial resistance often involves efflux pumps that expel antiseptics, similar mechanisms in viruses are not well-documented. HSV-1 lacks the complex machinery to develop such resistance mechanisms.

3. Biofilm Formation:

- Biofilm Resistance: Some pathogens form biofilms that protect them from antiseptics. HSV-1, however, does not form biofilms, reducing the likelihood of this resistance mechanism.

Prevalence of Resistant Strains

1. Current Data:

- Lack of Reports: There are no significant reports of HSV-1 strains resistant to CPC. Most studies and clinical reports indicate continued effectiveness of CPC-containing mouthwashes against HSV-1.

2. Comparative Resistance:

- Resistance to Antivirals: Resistance to specific antivirals like acyclovir can occur in HSV-1, especially in immunocompromised patients. In contrast, resistance to CPC is not documented, likely due to its broad and non-specific action.

3. Surveillance:

- Monitoring: Continuous monitoring of antiviral resistance is essential. However, the current understanding suggests that the risk of developing resistance to CPC is minimal (111).

4.7 Formulation and Administration

4.7.1 Formulation and Administration of Acyclovir Against HSV-1

1. Ease of Use:

Acyclovir is available in various formulations, each with its own advantages:

- Oral Formulation: Tablets and capsules are convenient for systemic treatment. Oral acyclovir is commonly prescribed for initial and recurrent HSV-1 infections. It is easy to administer, though its bioavailability is relatively low (15%-30%).

- Topical Formulation: Creams and ointments are applied directly to lesions, offering localized treatment with minimal systemic absorption. This is ideal for patients with mild outbreaks or those who prefer not to take oral medication.

- Intravenous Formulation: Used for severe HSV infections or for immunocompromised patients who require higher systemic concentrations of the drug. IV administration ensures rapid delivery of acyclovir to the bloodstream.

- Ophthalmic Formulation: Acyclovir eye ointment is used for HSV keratitis, ensuring direct delivery to the site of infection in the eye.

2. Frequency of Administration:

The dosing frequency of acyclovir varies by formulation and severity of infection:

- Oral Formulation: Typically administered 5 times daily for active infections or 2-3 times daily for suppressive therapy. High frequency is necessary due to its short half-life.

- Topical Formulation: Applied to lesions 5 times daily. Regular application is essential for optimal effectiveness.

- Intravenous Formulation: Administered every 8 hours. Frequent dosing is required to maintain therapeutic levels.

- Ophthalmic Formulation: Applied 5 times daily until healing, then 3 times daily for 7 days. This regimen ensures continuous antiviral activity at the site of infection.

3. Patient Preference:

Patient preference can influence the choice of formulation:

- Convenience: Oral tablets are generally preferred for convenience and ease of use. They are suitable for most patients with mild to moderate infections.

- Localized Treatment: Patients with localized lesions may prefer topical formulations to avoid systemic side effects and target the infection site directly.

- Severity of Infection: Patients with severe or disseminated infections, or those who are immunocompromised, may require IV acyclovir for effective treatment.

- Specific Needs: Patients with ocular HSV infections will need ophthalmic preparations to ensure proper treatment of the eye (112).

4.7.2 Formulation and Administration of CPC Mouthwash

Ease of Use

1. Oral Use:

➢ Simple Application: CPC mouthwash is designed for easy oral use. Patients swish the mouthwash around the mouth for a specified time (usually 30 seconds to 1 minute) before spitting it out.

➢ No Special Equipment: No additional tools or devices are required, making it convenient and straightforward.

2. Topical Alternatives.:

➢ Not Common for CP: CPC is primarily used in oral formulations such as mouthwashes. Topical formulations for other types of infections or conditions are less common but can be found in some antiseptic products.

Frequency of Administration

1. Typical Usage:

➢ Twice Daily: Most CPC mouthwash products recommend use twice daily, usually after brushing teeth, to maximize effectiveness.

➢ Additional Uses: For acute outbreaks or severe symptoms, more frequent use might be recommended, as per the product's instructions or a healthcare provider's advice.

2. Duration of Use:

➢ Short-Term and Long-Term: For managing outbreaks, CPC mouthwash is used until symptoms improve. For prophylactic use or preventing recurrences, consistent daily use is advised.

Patient Preference

1. Convenience:

➢ Ease of Integration: CPC mouthwash integrates easily into daily oral hygiene routines. Its use does not require significant changes to existing habits.

➢ No Discomfort: Most patients find mouthwash use to be comfortable and non-invasive compared to other treatment options.

2. Taste and Sensation:

➢ Flavour Options: CPC mouthwashes are available in various flavors, which can enhance patient compliance and satisfaction. Flavoured options can help mask any unpleasant taste associated with the active ingredient.

➢ Sensory Experience: Some patients may experience a mild burning sensation or altered taste, but this is generally well-tolerated.

3. Patient Feedback:

➢ Positive Reception: Many patients prefer mouthwashes for their ease of use and lack of need for specialized application methods. The quick and simple application contributes to high satisfaction rates (113).

Results:

Introduction:

HSV-1 is a significant cause of oral infections, often leading to painful vesicular eruptions. The virus has a broad host range and a rapid replication cycle. Recurrent infections, particularly in immunocompromised individuals, pose substantial clinical challenges. This review examines the effectiveness of acyclovir and CPC-containing mouthwash in managing HSV-1 infections.

Evaluation:

➢ Antiviral Efficacy: Acyclovir is well-documented for its potent antiviral activity by inhibiting HSV-1 DNA polymerase. It is effective in both in vitro and clinical settings, reducing the severity and duration of infections. CPC, through its surfactant action, disrupts the viral envelope, showing efficacy against HSV-1 in laboratory studies.

➢ Speed of Action: Acyclovir is most effective when administered during the prodromal phase of infection. CPC mouthwashes can quickly reduce viral load in the oral cavity.

➢ Safety and Side Effects: Acyclovir is generally safe but resistance can develop, particularly in immunocompromised patients. CPC is approved for oral use and is considered safe at recommended concentrations.

➢ Cost-Effectiveness: CPC-containing mouthwashes are cost-effective, readily available, and easy to use, making them a viable adjunct to acyclovir treatment.

➢ Mechanisms of Action: Acyclovir targets viral DNA synthesis, while CPC disrupts the viral envelope, highlighting different mechanisms that could be synergistic in combination therapy.

While acyclovir is effective in managing HSV-1, resistance remains a concern. CPC-containing mouthwashes offer an additional, cost-effective means to reduce viral load and transmission. Further clinical studies are needed to confirm the synergistic potential of combining these treatments.

Discussion:

The review highlighted that CPC-containing mouthwash and Acyclovir both possess significant antiviral properties against HSV-1, yet their mechanisms differ, with CPC primarily disrupting the viral envelope to reduce viral load and prevent new infections, and Acyclovir inhibiting viral DNA synthesis within infected cells. The study confirmed that CPC effectively reduces viral load and minimizes transmission risk by disrupting the viral envelope, consistent with existing literature supporting CPC's broad-spectrum antimicrobial properties, including efficacy against enveloped viruses like HSV-1. The combination of CPC with Acyclovir provides a complementary approach, with CPC acting topically to reduce viral load and Acyclovir targeting viral replication at the cellular level, enhancing overall antiviral efficacy. The combined use of CPC and Acyclovir could be a potent strategy in managing HSV-1 infections, offering both immediate reduction in viral load and long-term suppression of viral replication, improving treatment outcomes and patient comfort. However, the study had limitations, including potential variability in individual responses to CPC and Acyclovir and the need for consistent application of CPC to maintain viral load reduction. Future research should focus on long-term clinical trials to confirm these findings and explore the potential of combining CPC with other antiviral agents. Recommendations include integrating CPC mouthwash into standard HSV-1 treatment protocols, especially during active outbreaks, to enhance patient outcomes and reduce transmission rates.

Conclusion:

Acyclovir and CPC-containing mouthwashes both exhibit strong antiviral properties against HSV-1. Acyclovir remains a cornerstone of HSV-1 management due to its efficacy in reducing viral replication and clinical symptoms. CPC-containing mouthwashes provide a promising complementary approach due to their ability to disrupt the viral envelope, cost-effectiveness, and

ease of use. Combining these treatments could offer enhanced control of HSV-1 infections, particularly in reducing transmission and managing recurrent cases. Future research should focus on clinical trials to evaluate the combined efficacy of acyclovir and CPC-containing mouthwashes.

References:

1. Arduino PG, Porter SR. Herpes Simplex Virus Type 1 infection: Overview of relevant clinicopathological features. Journal of oral pathology & medicine. 2008 Feb;37(2):107-21.
2. Whitley RJ, Roizman B. Herpes simplex virus infections. The lancet. 2001 May 12;357(9267):1513-8.
3. Grunewald K, Desai P, Winkler DC, Heymann JB, Belnap DM, Baumeister W, Steven AC. Three-dimensional structure of herpes simplex virus from cryo-electron tomography. Science. 2003 Nov 21;302(5649):1396-8.
4. Booy FP, Newcomb WW, Trus BL, Brown JC, Baker TS, Steven AC. Liquid-crystalline, phage-like packing of encapsidated DNA in herpes simplex virus. Cell. 1991 Mar 8;64(5):1007-15.
5. Zhou ZH, Dougherty M, Jakana J, He J, Rixon FJ, Chiu W. Seeing the herpesvirus capsid at 8.5 Å. Science. 2000 May 5;288(5467):877-80.
6. Newcomb WW, Trus BL, Cheng N, Steven AC, Sheaffer AK, Tenney DJ, Weller SK, Brown JC. Isolation of herpes simplex virus procapsids from cells infected with a protease-deficient mutant virus. Journal of virology. 2000 Feb 15;74(4):1663-73.
7. Quinn JP, Dalziel RG, Nash AA. Herpes virus latency in sensory ganglia—a comparison with endogenous neuronal gene expression. Progress in neurobiology. 2000 Feb 1;60(2):167-79.
8. Ward PL, Roizman B. Herpes simplex genes: The blueprint of a succesful human pathogen. Trends in Genetics. 1994 Aug 1;10(8):267-74.
9. Scully C. Orofacial herpes simplex virus infections: current concepts in the epidemiology, pathogenesis, and treatment, and disorders in which the virus may be implicated. Oral surgery, oral medicine, oral pathology. 1989 Dec 1;68(6):701-10.
10. Amir J. Clinical aspects and antiviral therapy in primary herpetic gingivostomatitis. Paediatric drugs. 2001 Aug;3:593-7.
11. Ajar AH, Chauvin PJ. Acute herpetic gingivostomatitis in adults: a review of 13 cases, including diagnosis and management. Journal-Canadian Dental Association. 2002 Apr;68(4):247-51.
12. Cesario TC, Poland JD, Wulff H, Chin TDY, Wenner HA. Six years' experience with herpes simplex virus in a children's home. Am J Epidemiol. 1969;90:416–22.
13. Becker TM, Magder L, Harrison HR, et al. The epidemiology of infection with the human herpes viruses in Navajo children. Am J Epidemiol. 1998;127:1071–8.
14. Schmitt DL, Jonson DW, Henderson FW. Herpes simplex virus type 1 infection in group day care. Pediatr Infect Dis. 1991;10:729–34.
15. Huber MA. Herpes simplex type-1 virus infections. Quintessence Int. 2003;34:453–67.
16. Eisen D. The clinical characteristics of intraoral herpes simplex virus infection in 52 immunocompetent patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:432–7.
17. Amir J, Harel L, Smetana Z, Varsano I. The natural history of primary herpes simplex type 1 gingivostomatitis in children. Pediatr Dermatol. 1999;16:259–63.Scully C. Are viruses associated with aphthae and oral vesiculoerosive disorders? Br J Oral Maxillofac Surg. 1993;31:173–7.
18. Yura Y, Kusaka J, Yamakawa R, Bando T, Yoshida H, Sato M. Mental nerve neuropathy as a result of primary herpes simplex virus infection in the oral cavity. A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:306–9.
19. Holbrook WP, Gudmundsson GT, Ragnarsson KT. Herpetic gingivostomatitis in otherwise healthy adolescents and young adults. Acta Odontol Scand. 2001;59:113–5.
20. Scully C. Ulcerative stomatitis, gingivitis, and skin lesions. An unusual case of primary herpes simplex infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1985;59:261–3.
21. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ. 1997;314:1800–3.
22. Simmons A. Clinical manifestations and treatment considerations of herpes simplex virus infection. J Infect Dis. 2002;186:71–7.
23. Liang GS, Daikos GL, Serfling U, et al. An evaluation of oral ulcers in patients with AIDS and AIDS-related complex. J Am Acad Dermatol. 1993;29:563–8.
24. Itin PH, Lautenschlager S. Viral lesions of the mouth in HIV-infected patients. Dermatology. 1997;194:1–7.
25. Ehrilich J, Cohen GH, Hocman N. Specific Herpes simplex virus antigen in human gingiva. J Periodontol. 1983;54:357–60.
26. Heldwein EE, Krummenacher C. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci. 2008;65(11):1653–1668.
27. Martinez-Martin N, Viejo-Borbolla A, Martin R, et al. Herpes simplex virus enhances chemokine function through modulation of receptor trafficking and oligomerization. Nat Commun. 2015;6(1):6163.
28. Adamiak B, Ekblad M, Bergstrom T, et al. Herpes simplex virus type 2 glycoprotein G is targeted by the sulfated oligo- and polysaccharide inhibitors of virus attachment to cells. J Virol. 2007;81(24):13424–13434.

29. Spear PG, Eisenberg RJ, Cohen GH. Three classes of cell surface receptors for alphaherpesvirus entry. Virology. 2000;275(1):1–8.
30. Satoh T, Arii J, Suenaga T, et al. PILRα is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell. 2008;132(6):935–944.
31. Suenaga T, Satoh T, Somboonthum P, et al. Myelin- associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses. Proc Natl Acad Sci U S A. 2010;107(2):866–871.
32. Arii J, Goto H, Suenaga T, et al. Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1. Nature. 2010;467(7317):859–862.
33. 33. Gianni T, Salvioli S, Chesnokova LS, et al. alphavbeta6- and alphavbeta8-integrins serve as interchangeable receptors for HSV gH/gL to promote endocytosis and activation of membrane fusion. PLoS Pathog. 2013;9(12):e1003806.
34. Kopp SJ, Karaba AH, Cohen LK, et al. Pathogenesis of neonatal herpes simplex 2 disease in a mouse model is dependent on entry receptor expression and route of inoculation. J Virol. 2013;87(1):474–481.
35. Taylor JM, Lin E, Susmarski N, et al. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe. 2007;2(1):19–28.
36. Kopp SJ, Banisadr G, Glajch K, et al. Infection of neurons and encephalitis after intracranial inoculation of herpes simplex virus requires the entry receptor nectin-1. Proc Natl Acad Sci U S A. 2009;106(42):17916–17920.
37. Karaba AH, Kopp SJ, Longnecker R. Herpesvirus entry mediator is a serotype specific determinant of pathogenesis in ocular herpes. Proc Natl Acad Sci U S A. 2012;109(50):20649–20654.
38. Hilterbrand AT, Heldwein EE. Go go gadget glycoprotein!: HSV-1 draws on its sizeable glycoprotein tool kit to customize its diverse entry routes. PLoS Pathog. 2019;15(5):e1007660.
39. Aggarwal A, Miranda-Saksena M, Boadle RA, et al. Ultrastructural visualization of individual tegument protein dissociation during entry of herpes simplex virus 1 into human and rat dorsal root ganglion neurons. J Virol. 2012;86(11):6123–6137.
40. Dohner K, Wolfstein A, Prank U, et al. Function of dynein and dynactin in herpes simplex virus capsid transport. Mol Biol Cell. 2002;13(8):2795–2809.
41. Radtke K, Kieneke D, Wolfstein A, et al. Plus- and minus-end directed microtubule motors bind simultaneously to herpes simplex virus capsids using different inner tegument structures. PLoS Pathog. 2010;6(7):e1000991.
42. Sodeik B, Ebersold MW, Helenius A. Microtubule- mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J Cell Biol. 1997;136(5):1007–1021.
43. Wolfstein A, Nagel CH, Radtke K, et al. The inner tegument promotes herpes simplex virus capsid motility along microtubules in vitro. Traffic. 2006;7(2):227–237.
44. Musarrat F, Chouljenko V, Kousoulas KG. Cellular and viral determinants of HSV-1 entry and intracellular transport towards nucleus of infected cells. J Virol. 2021;95(7). DOI:10.1128/JVI.02434-20
45. Richards AL, Sollars PJ, Pitts JD, et al. The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion. PLoS Pathog. 2017;13(12):e1006741.
46. Brandariz-Nunez A, Liu T, Du T, et al. Pressure-driven release of viral genome into a host nucleus is a mechanism leading to herpes infection. Elife. 2019;8. DOI:10.7554/eLife.47212
47. Wysocka J, Herr W. The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem Sci. 2003;28(6):294–304.
48. Heming JD, Conway JF, Homa FL. Herpesvirus capsid assembly and DNA packaging. Adv Anat Embryol Cell Biol. 2017;223:119–142.
49. Dohner K, Ramos-Nascimento A, Bialy D, et al. Importin alpha1 is required for nuclear import of herpes simplex virus proteins and capsid assembly in fibroblasts and neurons. PLoS Pathog. 2018;14(1):e1006823.
50. Johnson DC, Baines JD. Herpesviruses remodel host membranes for virus egress. Nat Rev Microbiol. 2011;9(5):382–394.
51. Wu S, Pan S, Zhang L, et al. Herpes simplex virus 1 induces phosphorylation and reorganization of lamin A/C through the gamma134.5 Protein that facilitates nuclear egress. J Virol. 2016;90(22):10414–10422.
52. Liu Z, Kato A, Shindo K, et al. Herpes simplex virus 1 UL47 interacts with viral nuclear egress factors UL31, UL34, and Us3 and regulates viral nuclear egress. J Virol. 2014;88(9):4657–4667.
53. Liu Z, Kato A, Oyama M, et al. Role of host cell p32 in herpes simplex virus 1 De-envelopment during viral nuclear egress. J Virol. 2015;89(17):8982–8998.
54. Mou F, Forest T, Baines JD. US3 of herpes simplex virus type 1 encodes a promiscuous protein kinase that phosphorylates and alters localization of lamin A/C in infected cells. J Virol. 2007;81(12):6459–6470.
55. Funk C, Ott M, Raschbichler V, et al. The herpes simplex virus protein pUL31 escorts nucleocapsids to sites of nuclear egress, a process coordinated by its N-terminal domain. PLoS Pathog. 2015;11(6):e1004957.
56. Turcotte S, Letellier J, Lippe R. Herpes simplex virus type 1 capsids transit by the trans-Golgi network, where viral glycoproteins accumulate independently of capsid egress. J Virol. 2005;79(14):8847–8860.
57. Hollinshead M, Johns HL, Sayers CL, et al. Endocytic tubules regulated by Rab GTPases 5 and 11 are used for envelopment of herpes simplex virus. EMBO J. 2012;31(21):4204–4220.

58. Miranda-Saksena M, Boadle RA, Armati P, et al. In rat dorsal root ganglion neurons, herpes simplex virus type 1 tegument forms in the cytoplasm of the cell body. J Virol. 2002;76(19):9934–9951.
59. Morrison EE, Stevenson AJ, Wang YF, et al. Differences in the intracellular localization and fate of herpes simplex virus tegument proteins early in the infection of Vero cells. J Gen Virol. 1998;79(Pt 10):2517–2528.
60. Donnelly M, Elliott G. Nuclear localization and shuttling of herpes simplex virus tegument protein VP13/ 14. J Virol. 2001;75(6):2566–2574.
61. Bucks MA, O'Regan KJ, Murphy MA ,et al. Herpes simplex virus type 1 tegument proteins VP1/2 and UL37 are associated with intranuclear capsids. Virology. 2007;361(2):316–324.
62. Trus BL, Newcomb WW, Cheng N, et al. Allosteric signaling and a nuclear exit strategy: binding of UL25/ UL17 heterodimers to DNA-filled HSV-1 capsids. Mol Cell. 2007;26(4):479–489.
63. Ahmad I, Wilson DW. HSV-1 cytoplasmic envelopment and egress. Int J Mol Sci. 2020;21(17):5969.
64. Owen DJ, Crump CM, Graham SC. Tegument assembly and secondary envelopment of alphaherpesviruses. Viruses. 2015;7(9):5084–5114.
65. Reynolds AE, Wills EG, Roller RJ, et al. Ultrastructural localization of the herpes simplex virus type 1 UL31, UL34, and US3 proteins suggests specific roles in primary envelopment and egress of nucleocapsids. J Virol. 2002;76(17):8939–8952.
66. Shanda SK, Wilson DW. UL36p is required for efficient transport of membrane-associated herpes simplex virus type 1 along microtubules. J Virol. 2008;82(15):7388–7394.
67. Ivanova L, Buch A, Dohner K, et al. Conserved tryptophan motifs in the large tegument protein pUL36 are required for efficient secondary envelopment of herpes simplex virus capsids. J Virol. 2016;90(11):5368–5383.
68. Wagstaff AJ, Faulds D, Goa KL. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994 Jan;47:153-205.
69. Acosta EP, Fletcher CV. Valacyclovir. Annals of Pharmacotherapy. 1997 Feb;31(2):185-91.
70. Andrei G, Georgala A, Topalis D, Fiten P, Aoun M, Opdenakker G, Snoeck R. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. The Journal of infectious diseases. 2013 Apr 15;207(8):1295-305
71. Darby G, Field HJ, Salisbury SA. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981 Jan 1;289(5793):81-3.
72. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1–infected persons. Clinical infectious diseases. 2006 Aug 1;43(3):347-56.
73. Gerba CP. Quaternary ammonium biocides: efficacy in application. Applied and environmental microbiology. 2015 Jan 15;81(2):464-9.
74. Teng F, He T, Huang S, Bo CP, Li Z, Chang JL, Liu JQ, Charbonneau D, Xu J, Li R, Ling JQ. Cetylpyridinium chloride mouth rinses alleviate experimental gingivitis by inhibiting dental plaque maturation. International journal of oral science. 2016 Sep;8(3):182-90.
75. Mao, X.; Aue, D.L.; Buchalla, W.; Hiller, K.A.; Maisch, T.; Hellwig, E.; Al-Ahmad, A.; Cieplik, F. Cetylpyridinium Chloride: Mechanism of Action, Antimicrobial Efficacy in Biofilms, and Potential Risks of Resistance. Antimicrob. Agents Chemother. 2020, 64, e00576-20.
76. Brookes ZL, Belfield LA, Ashworth A, Casas-Agustench P, Raja M, Pollard AJ, Bescos R. Effects of chlorhexidine mouthwash on the oral microbiome. Journal of dentistry. 2021 Oct 1;113:103768.
77. Popkin DL, Zilka S, Dimaano M, Fujioka H, Rackley C, Salata R, Griffith A, Mukherjee PK, Ghannoum MA, Esper F. Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against influenza viruses in vitro and in vivo. Pathogens & immunity. 2017;2(2):253.Vergara-Buenaventura A, Castro-Ruiz C. Use of mouthwashes against COVID-19 in dentistry. Br J Oral Maxillofac Surg. 2020;58:924-7.
78. Vergara-Buenaventura A, Castro-Ruiz C. Use of mouthwashes against COVID-19 in dentistry. British Journal of Oral and Maxillofacial Surgery. 2020 Oct 1;58(8):924-7.
79. Muñoz-Basagoiti J, Perez-Zsolt D, León R, Blanc V, Raïch-Regué D, Cano-Sarabia M, et al. Mouthwashes with CPC reduce the infectivity of SARS-CoV-2 variants in vitro. J Dent Res. 2021;100:1265-72. doi:10.1177/00220345211007401.
80. Takeda R, Sawa H, Sasaki M, Orba Y, Maishi N, Tsumita T, et al. Antiviral effect of cetylpyridinium chloride in mouthwash on SARS-CoV-2. Sci Rep. 2022;12:14050. doi:10.1038/s41598-022-18410-3.
81. Anderson ER, Patterson EI, Richards S, Pitol AK, Edwards T, Wooding D, et al. CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva. J Med Microbiol. 2022;71:001508. doi:10.1099/jmm.0.001508.
82. Alemany A, Perez-Zsolt D, Raïch-Regué D, Muñoz-Basagoiti J, Ouchi D, Laporte-Villar C, et al. Cetylpyridinium chloride mouthwash to reduce shedding of infectious SARS-CoV-2: a double-blind randomized clinical trial. J Dent Res. 2022;101:1450-6. doi:10.1177/00220345221102715.
83. Ferrer MD, Barrueco ÁS, Martinez-Beneyto Y, Mateos-Moreno MV, Ausina-Márquez V, García-Vázquez E, et al. Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2. Sci Rep. 2021;11:24392. doi:10.1038/s41598-021-03791-7.

84. Alzahrani MM, Bamashmous S, Alkharobi H, Alghamdi A, Alharbi RH, Hassan AM, et al. Mouth rinses efficacy on salivary SARS-CoV-2 viral load: a randomized clinical trial. J Med Virol. 2023;95:e28412. doi:10.1002/jmv.28412.
85. Tarragó-Gil R, Gil-Mosteo MJ, Aza-Pascual-Salcedo M, Alvarez MJL, Ainaga RR, Gimeno NL, et al. Randomized clinical trial to assess the impact of oral intervention with cetylpyridinium chloride to reduce salivary SARS-CoV-2 viral load. J Clin Periodontol. 2023;50:288-94. doi:10.1111/jcpe.13860.
86. Carrouel F, Valette M, Gadea E, Esparcieux A, Illes G, Langlois ME, et al. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial. Clin Microbiol Infect. 2021;27:1494-501. doi:10.1016/j.cmi.2021.05.007.
87. Riveira-Muñoz E, Garcia-Vidal E, Bañó-Polo M, León R, Blanc V, Clotet B, Ballana E. Cetylpyridinium chloride-containing mouthwashes show virucidal activity against herpes simplex virus type 1. Viruses. 2023 Jun 25;15(7):1433.
88. Takeda R, Sawa H, Sasaki M, Orba Y, Maishi N, Tsumita T, Ushijima N, Hida Y, Sano H, Kitagawa Y, Hida K. Antiviral effect of cetylpyridinium chloride in mouthwash on SARS-CoV-2. Scientific reports. 2022 Aug 18;12(1):14050.
89. Hung SL, Wang YH, Chen HW, Lee PL, Chen YT. Analysis of herpes simplex virus entering into cells of oral origin. Virus research. 2002 Jun 1;86(1-2):59-69.
90. Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994 Aug;48:199-226.
91. Elion GB. Mechanism of action and selectivity of acyclovir. The American journal of medicine. 1982 Jul 20;73(1):7-13.
92. Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase: mechanism of inhibition by acyclovir triphosphate. Journal of Biological Chemistry. 1989 May 5;264(13):7405-11.
93. Fisher PA, Korn D. Ordered sequential mechanism of substrate recognition and binding by KB cell DNA polymerase. alpha. Biochemistry. 1981 Aug;20(16):4560-9.
94. Howett MK, Neely EB, Christensen ND, Wigdahl B, Krebs FC, Malamud D, Patrick SD, Pickel MD, Welsh PA, Reed CA, Ward MG. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrobial agents and chemotherapy. 1999 Feb 1;43(2):314-21.
95. Alvarez DM, Duarte LF, Corrales N, Smith PC, González PA. Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts. Antiviral Research. 2020 Jul 1;179:104818.
96. Sreenivasan PK, Haraszthy VI, Zambon JJ. Antimicrobial efficacy of 0· 05% cetylpyridinium chloride mouthrinses. Letters in applied microbiology. 2013 Jan 1;56(1):14-20.
97. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints.
98. Alvarez DM, Duarte LF, Corrales N, Smith PC, González PA. Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts. Antiviral Research. 2020 Jul 1;179:104818.
99. Fisher PA, Korn D. Ordered sequential mechanism of substrate recognition and binding by KB cell DNA polymerase. alpha. Biochemistry. 1981 Aug;20(16):4560-9.
100. Capps C, inventor; ViraTox LLC, assignee. Virucidal activities of cetylpyridinium chloride. United States patent application US 10/703,969. 2005 May 12.
101. Datta AK, Pagano JS. Phosphorylation of acyclovir in vitro in activated Burkitt somatic cell hybrids. Antimicrobial Agents and Chemotherapy. 1983 Jul;24(1):10-4.
102. Muñoz-Basagoiti J, Perez-Zsolt D, León R, Blanc V, Raïch-Regué D, Cano-Sarabia M, et al. Mouthwashes with CPC reduce the infectivity of SARS-CoV-2 variants in vitro. J Dent Res. 2021;100:1265-1272.
103. Andrei G, Snoeck R, Schols D, Goubau P, Desmyter J, De Clercq E. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. European Journal of Clinical Microbiology and Infectious Diseases. 1991 Dec;10:1026-33.
104. Badia R, Angulo G, Riveira-Muñoz E, Pujantell M, Puig T, Ramirez C, Torres-Torronteras J, Martí R, Pauls E, Clotet B, Ballana E. Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. Journal of Antimicrobial Chemotherapy. 2016 Feb 1;71(2):387-94.
105. Müller HD, Eick S, Moritz A, Lussi A, Gruber R. Cytotoxicity and antimicrobial activity of oral rinses in vitro. BioMed research international. 2017;2017(1):4019723.
106. Agut H, Huraux JM, Collandre H, Montagnier L. Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir. The Lancet. 1989 Sep 9;334(8663):626.
107. Carrouel F, Valette M, Gadea E, Esparcieux A, Illes G, Langlois ME, Perrier H, Dussart C, Tramini P, Ribaud M, Bouscambert-Duchamp M. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial. Clinical Microbiology and Infection. 2021 Oct 1;27(10):1494-501.
108. Collins P. The spectrum of antiviral activities of acyclovir in vitro and in vivo. Journal of Antimicrobial Chemotherapy. 1983 Jan 1;12(suppl_B):19-27.
109. Popkin DL, Zilka S, Dimaano M, Fujioka H, Rackley C, Salata R, Griffith A, Mukherjee PK, Ghannoum MA, Esper F. Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against influenza viruses in vitro and in vivo. Pathogens & immunity. 2017;2(2):253.

110. Field AK, Biron KK. " The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clinical microbiology reviews. 1994 Jan;7(1):1-3.
111. Yang SZ, Wu GY, Long M, Deng WW, Wang HN, Zou LK. Antibiotic and disinfectant resistance of Salmonella isolated from egg production chains. Yi Chuan= Hereditas. 2016 Oct 1;38(10):948-56.
112. Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, Fahnlander A, Remington M, Winter C, Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. New England Journal of Medicine. 1984 Jun 14;310(24):1551-6.
113. Davies RM. The clinical efficacy of triclosan/copolymer and other common therapeutic approaches to periodontal health. Clinical Microbiology and Infection. 2007 Oct;13:25-9.

How to cite this article:
Ms. Vaishali Patel et al. Ijppr.Human, 2024; Vol. 30 (8): 48-75.
Conflict of Interest Statement: All authors have nothing else to disclose.